BioBlast Pharma (ORPN) Strengthens Leadership Through Organizational Changes; Oppenheimer Reiterates Outperform

Oppenheimer reiterated an Outperform rating and $32.00 price target on Bio Blast Pharma (NASDAQ: ORPN) following announced organizational changes. ORPN appointed Warren Wasiewski, M.D. as CMO and VP Research & Development, Leigh Cherry as VP Manufacturing, and Stacey Jurchison as VP Investor Relations & Corporate Communications.

Analyst Ling Wang commented, "This morning, ORPN announced key organizational changes that strengthen its leadership team. With the significant global, clinical and operational experience of new management members, we see the new team as strengthened. We recently attended a Key Opinion Leader meeting featuring oculopharyngeal muscular dystrophy (OPMD) in New York City. Bernard Brais, an internationally renowned neurologist and professor of neurology and human genetics at McGill University, made a keynote presentation on OPMD. ORPN management also provided an overview of the ongoing clinical programs of Cabaletta."

For an analyst ratings summary and ratings history on Bio Blast Pharma click here. For more ratings news on Bio Blast Pharma click here.

Shares of Bio Blast Pharma closed at $4.50 yesterday.

You May Also Be Interested In

• Cleveland Research Upgrades Dynatrace Inc. (DT) to Buy, 'optimism underlying fundamentals are likely to support upside'
• CN (CNI) Brings Back Remi G. Lalonde as Chief Commercial Officer
• HSBC Upgrades Topdanmark (TOP:DC) (TPDKY) to Hold